Douglas Conklin has left Cold Spring Harbor Laboratory and has joined the cancer biology research team of the University at Albany Gen*NY*Sis Center for Excellence in Cancer Genomics.
“It’s just a better opportunity here,” Conklin told RNAi News. “There’s an awful lot going on here in terms of biotech and molecular biology research.”
At CSHL, Conklin worked closely with Greg Hannon studying RNAi. His research has appeared in a number of journals including Nature and Proceedings of the National Academy of Sciences, and he is the co-inventor of an issued patent — number 6,255,071 — covering mammalian viral vectors and their uses.
Now, at GCECG, Conklin said he is going to be working on “primarily genomics. The idea will be to use RNAi as a tool in testing all the genes that have now been found with the genome sequencing project for roles in cancer.”
According to the university, other newcomers to GCECG include Julio Aguirre-Ghiso, who comes from Mt. Sinai School of Medicine, and Scott Tenenbaum, a microbiology post-doc at Duke University.
Alnylam said that it has appointed Kevin Starr as an outside director of the board of Alnylam Holding, expanding the number of board members to eight.
According to the company, Starr held various positions at Millennium Pharmaceuticals (the former employer of Alynlam CEO John Maraganore) including COO and CFO, between 1998 and 2002. Prior to his time at Millennium, he was corporate controller and manager of financial analysis at Biogen.
William Linton has joined the board of directors of High Throughput Genomics, the Tuscon, Ariz., company said this week.
Linton is a founder and CEO of Promega, as well as a director for Bruker Biosciences and a member of the advisory board for the Medical College of Wisconsin’s cardiovascular center, as well as the Wisconsin Technology Council
Mary Holland and Mark Meyers have been appointed vice presidents of sales and marketing at EraGen Biosciences, the Madison, Wis., company said this week.
Holland, who will focus on marketing and sales of EraGen’s Aegis synthetic DNA product, comes to the company from San Diego-based Nanogen, where she was senior director of worldwide corporate accounts.
Meyers, who will develop sales and marketing strategies for the company’s Master Catalog proteomics system, was previously vice president of sales for San Mateo, Calif.-based Scimagix.